Takeda, Denali drop Alzheimer's asset after phase 1 peak reveals 'narrow...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 09, 2023 at 12:12: PM
via Takeda and Denali Therapeutics have made the joint decision to end work on their Alzheimer’s disease therapy after a glimpse at early phase 1 data suggested they couldn't pursue the highest dose tested.

article source
 

<



Similar threads

cafead
FDA denies Denali&#039;s Takeda-partnered Alzheimer&#039;s drug from entering clinic
Replies
0
Views
136
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Deal-hungry Takeda hands over $150M to Denali for neurodegenerative work
Replies
0
Views
181
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
US allows increased production of Takeda&#039;s ADHD drug to address shortage
Replies
0
Views
17
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
With a new oncology head, Takeda revamps its R&amp;D strategy
Replies
0
Views
42
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Lundbeck leaves Trintellix to partner Takeda in the US, opting for royalties as it focuses efforts on Rexulti
Replies
0
Views
17
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote